Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

13.99 +0.01 (+0.10%)
Streaming Delayed Price Updated: 3:29 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 Next >
Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
From Teva Pharmaceutical Industries Limited
Via Business Wire
U.S. Mental Health Access Program Expands Medicine Donation to Seven New States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Launch New Growth Strategy at Investor Day
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Complete Response Letter Received for AVT02 Biologics License Application
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
Teva to Present at the Barclays Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports Fourth Quarter and Full Year 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Teva Finalizes Nationwide Opioid Settlement Terms
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Appointment of Richard Francis as President and CEO
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.